美國居民不適用 XM 服務。

Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans</title></head><body>

SAO PAULO, Oct 3 (Reuters) -Germany's Bayer BAYGn.DE forecasts that some 30% of Brazil's soybean area will be sowed with its genetically modified biotech seed Intacta2 Xtend in the 2024/25 season, doubling the share from the previous crop, a top executive said this week.

The exact share Intacta2 Xtend will reach should be clear only in some two or three weeks after expected rains allow a broad planting in Brazil's soy fields, Bayer's head of regulatory science for Latin America Geraldo Berger told Reuters in an interview on Monday.


WHY IT'S IMPORTANT

Brazil, the world's largest soy producer and exporter, is Bayer's second largest market behind only the United States.


CONTEXT

Bayer's Intacta2 Xtend seed is designed to tolerate herbicides, including glyphosate and dicamba, and protects the plant against caterpillars.

Last year, Bayer had estimated that between 10% to 15% of Brazil's soybean area would be sowed with Intacta2 Xtend - the third generation of the genetically modified soybean - in the 2023/24 season.


KEY QUOTES

Bob Reiter, head of research and development for Bayer's crop science division, said the firm plans to launch a fourth generation of the product in the next 10 years.

"We always have to stay ahead of insect pressure and insect resistance risk and also improve the breadth of insects that we can try to control with biotechnology," he said.



Reporting by Roberto Samora; Writing by Andre Romani Pinto; Editing by Sandra Maler

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明